Wellington Partners

Wellington Partners

  • Home
  • Team
  • Approach
  • Portfolio
  • News
  • Contact

News

Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models

Details
Published: 24 March 2020
  • portfolio-news

Nature Biotechnology has published a study demonstrating Carisma's foundational technology evaluating the potential of human chimeric antigen receptor macrophages (CAR-M) for cancer immunotherapy. The preclinical findings indicate that CAR-M therapy could overcome the key challenges that cell therapies have encountered with solid tumors – limited trafficking to the tumor site, an immunosuppressive tumor microenvironment, and the heterogeneous expression of tumor-associated antigens. 

© Wellington Partners, 2021.
  • WP Technology Funds
  • Contact
  • Imprint
  • Privacy